AKTEN (Lidocaine Hydrochloride) Patent Expiration, LOE Window & CMS Spending

AKTEN (Lidocaine Hydrochloride) by Thea: FDA Orange Book core substance LOE 2026-07-24, 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorThea
FDA Application & PathwayN022221 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2026-07-24
Last Listed Patent or Exclusivity Date2026-07-24
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel